Department of Cardiac Surgery, West China Hospital, Sichuan University, Chengdu, China.
Department of Oncology, West China Hospital, Sichuan University, Chengdu, China.
J Thorac Cardiovasc Surg. 2013 Apr;145(4):1013-1017. doi: 10.1016/j.jtcvs.2012.05.009. Epub 2012 Jun 5.
The study objective was to evaluate the safety and efficacy of concomitant bipolar radiofrequency ablation and heart valve replacement in patients with rheumatic heart disease and atrial fibrillation.
A total of 191 patients with rheumatic heart disease and chronic atrial fibrillation underwent valve replacement with concomitant bipolar radiofrequency ablation. There were 78 male and 113 female patients with a mean age of 46.0 ± 9.1 years and an atrial fibrillation duration of 43.7 ± 15.4 months. Valve replacement surgery included mitral valve replacement in 121 patients, mitral and aortic valve replacement in 59 patients, mitral and tricuspid valve replacement in 8 patients, and triple valve replacement in 3 patients. All patients received oral antiarrhythmic drugs for 3 to 6 months postoperatively. Follow-up electrocardiography and color Doppler echocardiography were performed postoperatively.
The mean aortic crossclamping time was 84.0 ± 25.5 minutes, and cardiopulmonary bypass time was 139.4 ± 39.1 minutes. There was no abnormal bleeding due to bipolar radiofrequency ablation. Three patients (1.57%) died of low cardiac output syndrome in hospital at 2, 3, and 5 days after surgery. Major perioperative complications include reoperation for bleeding (n = 1), reoperation for wound infection (n = 1), intra-aortic balloon pump placement (n = 2), and renal failure (n = 2). All other patients were discharged without complications. The mean follow-up time was 17.4 ± 11.8 months with a follow-up rate of 95.3%. There were no cases of late death, complete atrioventricular block, or anticoagulation-induced complications. Of 158 patients who were followed up for 1 year, sinus rhythm was maintained in 125 (79.11%).
Concomitant bipolar radiofrequency ablation is an effective and safe technique for treating atrial fibrillation in patients with rheumatic heart disease undergoing valve replacement, with promising follow-up results.
本研究旨在评估风湿性心脏病合并心房颤动患者行双极射频消融同期心脏瓣膜置换术的安全性和有效性。
191 例风湿性心脏病合并慢性心房颤动患者行瓣膜置换术同期行双极射频消融术。其中男 78 例,女 113 例;年龄 46.0±9.1 岁;心房颤动病史 43.7±15.4 个月。瓣膜置换手术包括二尖瓣置换术 121 例,二尖瓣和主动脉瓣置换术 59 例,二尖瓣和三尖瓣置换术 8 例,三尖瓣置换术 3 例。所有患者术后均口服抗心律失常药物 3~6 个月。术后行心电图和彩色多普勒超声心动图检查。
主动脉阻断时间为 84.0±25.5 分钟,体外循环时间为 139.4±39.1 分钟。双极射频消融无异常出血。术后 2、3、5 天,3 例(1.57%)患者因低心排血量综合征死亡。主要围手术期并发症包括:出血再次手术 1 例,切口感染再次手术 1 例,主动脉内球囊反搏 2 例,肾衰竭 2 例。所有患者均无其他并发症出院。平均随访时间为 17.4±11.8 个月,随访率为 95.3%。无晚期死亡、完全性房室传导阻滞或抗凝相关并发症。158 例随访 1 年的患者中,窦性心律维持 125 例(79.11%)。
双极射频消融术是风湿性心脏病合并心房颤动患者行瓣膜置换术同期治疗心房颤动的一种有效且安全的技术,具有良好的随访结果。